Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation A modelling analysis from the Euro Heart Survey

Ron Pisters, Robby Nieuwlaat, Deirdre A. Lane, Harry J. G. M. Crijns, Gregory Y. H. Lip*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

44 Citations (Web of Science)
Original languageEnglish
Pages (from-to)328-336
JournalThrombosis and Haemostasis
Issue number2
Publication statusPublished - Feb 2013


  • Atrial fibrillation
  • oral anticoagulation
  • stroke prevention

Cite this